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Abstract: VB4-845 is a scFv-Pseudomonas exotoxin A fusion construct that targets epithelial 
cell adhesion molecule (EpCAM). A phase I trial was conducted to determine the maximum 
tolerated dose (MTD) of VB4-845 when administered as weekly intratumoral (IT) injections to 
patients with squamous cell carcinoma of the head and neck (SCCHN). Secondary objectives 
included the evaluation of the safety, tolerability, pharmacokinetic proﬁ  le, and immunogenic-
ity, and a preliminary assessment of tumor response. Twenty patients with advanced, recurrent 
SCCHN were treated weekly for four weeks in ascending dose cohorts of 100, 200, 330, 500, 
700, and 930 μg. The MTD was established as 930 μg with a dose limiting toxicity of elevated 
liver enzymes in two of ﬁ  ve patients. VB4-845 therapy was well tolerated with common treat-
ment-related adverse events of injection site reactions, fever, gastrointestinal disorders, and 
elevated liver enzyme levels. All patients developed antibodies to VB4-845 by the end of the 
study, but only seven patients had neutralizing antibodies. Preliminary efﬁ  cacy data found 
87.5% of EpCAM-positive patients had a positive response to VB4-845 therapy. Noninjected 
dermal metastases were also resolved in one patient. VB4-845 IT therapy is safe and feasible 
and warrants further clinical evaluation for the treatment of SCCHN.
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Introduction
Combined treatment regimes, such as chemoradiotherapy, have recently improved the 
prognosis of patients with squamous cell carcinoma of the head and neck (SCCHN) 
(Posner 2007); however response to second line treatment remains very low (León 
et al 2005). As such, new treatment options for these patients are urgently needed and 
a variety of molecules are currently under study (Haddad et al 2006; Bossi et al 2007; 
Le Tourneau et al 2007).
The use of monoclonal antibodies and immunotoxins offers target-speciﬁ  c and increas-
ingly effective treatment options where traditional therapies have failed (Robert et al 
2001; von Mehren et al 2003; MacDonald and Glover 2005; Bonner et al 2006; Pastan 
et al 2007; Gebbia et al 2007; Blick et al 2007). One such target, epithelial cell adhesion 
molecule (EpCAM or CD326), whose normal function is to mediate epithelium-speciﬁ  c, 
homotypic cell-cell adhesions (Litvinov et al 1994, 1997), is highly expressed in a variety 
of carcinomas (Balzar et al 1999; Winter et al 2003; Went et al 2004), including squamous 
cell carcinoma of the tongue (Yanamoto et al 2007), esophagus (Stoecklein et al 2006) and 
oral cavity (Laimer et al 2008), and thus represents an ideal target for immunotherapy.
VB4-845 is a recombinant fusion protein that combines the speciﬁ  city of an anti-
EpCAM single chain variable fragment (scFv) with the toxicity of Pseudomonas Drug Design, Development and Therapy 2008:2 106
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exotoxin A (ETA252–608) (Di Paolo et al 2003). Once bound 
to EpCAM via the scFv portion, the fusion construct is 
internalized through an endocytic pathway. An activated 
form of ETA is released into the cytosol following furin 
cleavage where it inhibits protein synthesis ultimately lead-
ing to cell death (Perentesis et al 1992; Pastan et al 2006). 
VB4-845 studies have previously shown signiﬁ  cant growth 
inhibition of EpCAM-positive, human tumor xenografts of 
colorectal cancer, small cell lung cancer, and SCCHN in mice 
(Di Paolo et al 2003). Other clinical studies using systemic 
administration of immunotoxins have resulted in vascular 
leak syndrome (VLS), a nonspeciﬁ  c inﬂ  ammatory response, 
as well as a dose-limiting immunogenic response (Siegall 
et al 1997; Pastan et al 2006). Therefore, we have chosen 
intratumoral (IT) administration (Rand et al 2000; Azemar 
et al 2003) to reduce the potential of VLS and minimize the 
effect of an anti-VB4-845 response. Drug concentrations 
were chosen based upon our preclinical results (Brown et al 
2005). This phase I dose-escalation trial was conducted in 
patients with advanced, recurrent SCCHN, where VB4-845 
was administered weekly for four consecutive weeks. The 
primary objective of this study was to determine the maxi-
mum tolerated dose (MTD) of VB4-845, while the secondary 
objectives evaluated the safety, tolerability, pharmacokinetic 
proﬁ  le, immunogenicity, and a preliminary determination of 
tumor response.
Patients and methods
Patient selection
Patients 18 years of age or older, with histologically con-
ﬁ  rmed recurrent SCCHN following radiotherapy and/or 
chemotherapy, were eligible for enrollment. At least one 
bidimensional, measurable target lesion that was amenable 
to direct injection was required. Key inclusion criteria 
were a Karnofsky performance status of at least 70 and an 
estimated life expectancy of more than three months. Fur-
ther inclusion criteria included demonstration of adequate 
hepatic function (alanine aminotransferase [ALT] and 
aspartate aminotransferase [AST] 2.5 times the upper limit 
of normal [ULN], and bilirubin levels ≤1.5 times ULN); 
adequate renal function (serum creatinine 1.5 times ULN, 
or creatinine clearance 60 mL/minute) and hematologic 
values required for inclusion were granulocytes 1500/μL, 
platelets 100 000/μL, and hemoglobin 8 g/dL. Key 
exclusion criteria included suspected or impending airway 
obstruction; suspected or documented carotid artery inﬁ  l-
tration by the injectable tumor; history of HIV, hepatitis C, 
hepatitis B, or brain metastasis; uncontrolled hypertension; 
a prior splenectomy; treatment within four weeks prior to 
screening with systemic corticosteroids, any other mono-
clonal antibody, investigational product, or radiotherapy; 
concurrent diseases that might affect interpretation of the 
study results, including clinically signiﬁ  cant renal or hepatic 
disease; surgery with general anesthetic scheduled within 
four weeks of screening.
The study was conducted in accordance with the Declara-
tion of Helsinki, International Conference on Harmonization 
guideline E6 (Good Clinical Practice), Title 21, Parts 50 and 
56 of the United States Code of Federal Regulations and with 
the laws and regulations for the conduct of human clinical 
trials in Brazil, including the Institutional Review Board. 
Independent Ethics Committee (IEC) approval was obtained 
prior to initiating the study. Written informed consent was 
obtained from each patient before any study-related activity 
was performed.
Study design and dose escalation
The study was an open-label, multicenter, single-arm 
dose-escalating trial assessing the safety and tolerability 
of VB4-845 injected IT once weekly for four consecutive 
weeks. Twenty patients were treated in six dose cohorts, 
and were followed for four weeks after the last dose. The 
ascending modiﬁ  ed Fibonacci dose cohorts were 100, 200, 
330, 500, 700, and 930 μg. VB4-845 was supplied as a 
1 mg/mL formulation and was diluted in phosphate buffered 
saline. Depending on the size and location of the tumor, 
VB4-845 was either administered from a single puncture 
site or from multiple sites in one cm increments evenly 
distributed throughout the tumor. Brieﬂ  y, a 25 to 27 gauge 
needle attached to 1 cc Luer-lock syringe was inserted into 
the base of the tumor at approximately a 45-degree angle. If 
blood appeared with a slight draw of the syringe, the needle 
was removed and reinserted in a different area of the tumor. 
Drug was only administered if no blood was observed. The 
suspension volume of PBS used for immunotoxin administra-
tion was equal to that required to bring the total dose volume 
to no more than 30% of the estimated volume of the tumor 
mass being injected. Depending on the size and location 
of the tumor, the injection was completed by tracking the 
product through the tumor from a single puncture site or by 
injecting the tumor from multiple sites, in 1 cm increments, 
in parallel rows approximately 0.5 to 1.0 cm apart and dis-
bursing throughout the tumor. While the speed of injection 
was not dictated, the speed of injection generally depended 
upon the density of the tumor tissue and the ease of disburs-
ing the study drug solution throughout the tumor while still Drug Design, Development and Therapy 2008:2 107
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allowing the retention of the study drug within the tumor. 
It should be noted that the selection of appropriate target 
tumors excluded those involving critical structures. The far 
majority of tumors were treatable without image guidance 
in the outpatient setting; however, image guidance with, for 
example, ultrasound or computed tomography (CT) was not 
discouraged.
At least three patients were enrolled in each dose cohort 
and dose escalation was permitted once two patients had 
completed the ﬁ  rst two weeks of dosing without dose-limiting 
toxicity (DLT). The DLT was deﬁ  ned as the occurrence 
of adverse events related to treatment including: grade 4 
toxicity for local reaction at the injection site, grade 4 ﬂ  u-
like symptoms, grade 4 hematological toxicity, or any other 
nonhematological grade 3 toxicities with the exception of 
alopecia. If two patients experienced DLT at any dose, that 
dose was deﬁ  ned as the MTD.
Safety was evaluated by monitoring adverse events, 
hematology, blood chemistry/serology, and urinalysis, and 
regular physical examinations. The toxicity grade of an 
adverse event was classiﬁ  ed according to the National Cancer 
Institute (NCI) common toxicity criteria (CTC), version 2.0. 
In order to fully characterize the local effects of IT VB4-845 
administration, a local injection toxicity scale was included, 
based on the injection site reaction event in NCI CTC version 
2.0 (see Table 2). Adverse events were judged to be treatment-
related by the investigators if they were possibly, probably, 
or deﬁ  nitely related to VB4-845 administration.
Patient evaluation
Pretreatment screening evaluations were performed within 
two weeks of the baseline visit and included: history and 
physical examination; 12-lead electrocardiogram; identi-
ﬁ  cation, measurement, and digital photography of target 
and nontarget tumors; chest radiograph; urinalysis, blood 
collection for serum chemistry, and hematology and biopsy. 
Immunohistochemistry on tissue biopsies was performed to 
determine EpCAM expression in tumors. Baseline evalua-
tions on day one of drug administration included assessment 
of Karnofsky performance status, and a physical examination. 
Prior to dosing on days 1, 8, 15, and 22, and in the follow-
up period (weeks 4, 6, and 8) vital signs were recorded, and 
urinalysis, blood biochemistry and hematological analyses 
were performed. Vital signs and adverse events were assessed 
for 24 hours post dose. Measurements of the target and 
nontarget tumors were performed prior to treatment and at 
weeks 4 and 8 using CT and caliper measurements and pain 
was also assessed. At the end of week 8 (or the patient’s ﬁ  nal 
visit) additional analyses included assessment of Karnofsky 
performance status, digital photographs of observable 
lesions, 12-lead electrocardiogram, and pregnancy test for 
nonsterile females of reproductive age.
Pharmacokinetics
Blood samples for pharmacokinetic analysis were taken on 
day one prior to drug injection and after dosing at 10 and 
30 minutes, and at 1, 2, 4, 6, 12, and 24 hours, and prior 
to dosing on days 8, 15, 22, and at the end of week four. 
The amount of VB4-845 in the plasma was evaluated by a 
potency assay using VB4-845-mediated cytotoxicity on the 
EpCAM-positive CAL-27 cell line (ATCC, Manassas, VA, 
USA). Patient samples or VB4-845 standards were incubated 
with pre-cultured CAL-27 cells at 37 °C under 5% CO2 for 
72 hours, and washed with PBS-T (PBS with 0.5% polysor-
bate; Sigma Aldrich, St. Louis, MO, USA). Cell viability 
was determined using MTS reagent (tetrazolium compound; 
Promega, Madison, WI, USA) and the absorbance was read 
(Vmax, Molecular Devices, Sunnyvale, CA, USA). The 
amount of VB4-845 present in patient plasma was interpo-
lated from the calibration curve of VB4-845 standards diluted 
in normal plasma.
Immunogenicity
Blood samples for assessing humoral immune reactivity to 
VB4-845 were collected as for the pharmacokinetic analysis 
on days 1, 8, 15, 22, 28 prior to administration of VB4-
845, and day 56. Antibody titers to the antibody fragment 
(anti-scFv), and the toxin portion (anti-ETA(252–608)) were 
measured using ELISA. Brieﬂ  y, either puriﬁ  ed ETA1–608 
(Sigma Aldrich) or the human scFv moiety (4D5 scFv) were 
diluted to 14 nM in carbonate buffer (pH 9.6) and coated onto 
ELISA plates overnight at 4 °C. The plates were washed and 
blocked, and serially-diluted patient plasma samples (PBS, 
1% BSA) were added to the coated plates for 2 hours at 
room temperature. Antibodies to ETA1–608 or 4D5 scFv were 
detected by adding HRP-labeled goat antihuman-IgG, IgM, 
IgA (H + L) antibodies (KPL, Gaithersburg, MD, USA) for 
1 hour at RT, followed by washing and the addition of TMB 
(3,3’,5,5’ tetramethylenzidine; KPL) and the absorbance 
read (Vmax). The minimum required dilution of the plasma 
samples to avoid interference was 1/1000 and the cut-off 
value for positivity was deﬁ  ned as 4x standard deviation of 
the O.D. of the blank buffer samples, ie, 0.1 O.D. To assess 
whether the patients had cross-reactive antibodies prior to 
treatment, the mean titer on Day 1 was expressed only as the 
geometric mean of the reciprocal dilution at 0.1 O.D. For all Drug Design, Development and Therapy 2008:2 108
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other days, the patient immune response measured follow-
ing VB4-845 administration was expressed as the geometric 
mean of the reciprocal dilution at 0.1 O.D. after subtracting 
the pre-treatment sample (Day 1) O.D. value.
Results
Patient characteristics
A total of 20 patients were enrolled, all of whom had recur-
rent, advanced SCCHN (Table 1). Ninety percent of patients 
had received at least one cycle of chemotherapy and all had 
received radiotherapy. Patient enrollment was independent 
of tumor EpCAM status: 18 patients had EpCAM-positive 
tumors and two patients had EpCAM-negative tumors.
Dose escalation, safety, and maximum 
tolerated dose
The study progressed through doses of 100, 200, 330, 500, 
and 700 μg, and was terminated at 930 μg upon reaching the 
MTD. Dosing was once weekly for four consecutive weeks, 
with a four week follow-up. Eight patients discontinued the 
study due to death unrelated to VB4-845 administration, 
withdrawal of consent, or adverse events.
All 20 patients reported at least one adverse event during 
the course of the study, with common adverse events including 
injection site reactions, tumor pain, gastrointestinal disorders, 
elevated liver enzymes, tumor bleeding, dehydration and 
fever. Treatment-related adverse events were reported by 
16 patients (80%) and are summarized in Table 2. Except 
for one instance of a grade 4 event (elevated gamma-glu-
tamyltranspeptidase: GGT) in the 700 μg cohort, all treat-
ment-related adverse events were grade 3 or lower. The most 
frequent treatment-related adverse events were injection site 
reactions, which included tumor pain, edema, and/or ery-
thema. Other treatment-related adverse events included fever, 
ﬂ  u-like symptoms (including anorexia, nausea, and vomiting), 
and elevated liver enzyme tests. In general, these adverse 
events were reported by patients across all dose cohorts. The 
most common treatment-related adverse event, injection site 
reactions, was not unexpected and was manageable.
Elevated liver enzyme levels (AST, ALT, and GGT) 
occurred in one patient in the 700 μg cohort, and three 
patients at the 930 μg dose level. Two patients in the 930 μg 
dose cohort experienced grade 3 elevated liver enzyme lev-
els after the ﬁ  rst two doses and this was determined to be 
the DLT and these patients discontinued treatment. In one 
patient, this adverse event was resolved within 13 days when 
liver functions returned to normal. The other patient died 
seven days after the second dose, from grade 4 multiple organ 
failure, which was considered to be due to disease progression 
rather than to VB4-845 administration. Of the four patients 
with elevated liver enzyme levels, three had the highest 
VB4-845 plasma concentration with maximum concentra-
tion (Cmax) values ranging from 18,809–49,363 pg/mL. 
It is well documented that EpCAM is not expressed on 
adult hepatocytes but is detectable on bile duct epithelium 
(De Boer et al 1999; Schmelzer and Reid 2008). Patients 
with elevated liver enzyme levels did not present with any 
overt signs of liver damage or toxicity such as abdominal 
pain, tenderness, enlarged liver, jaundice, or even signs 
of decreased synthetic capacity of the liver due to severe 
liver damage such as coagulopathy or edema. Moreover, no 
indication of bile duct obstruction was observed, the predicted 
outcome with bile duct epithelial injury. As the patients with 
elevated enzymes, for whom follow-up was available, were 
asymptomatic and the levels were transient and reversible, the 
most likely explanation for the enzyme levels is an increase 
in physiologic activity of hepatocytes in response to drug 
clearance. Interestingly, the two patients treated at the highest 
dose level that did not exhibit any DLTs associated with an 
increase in liver enzymes had been pre-sensitized to ETA. 
This would suggest that the pre-existing antibody response 
may have afforded a degree of protection against hepatic 
changes attributed to circulating drug.
Table 1 Patient characteristics
Total number of patients  20
Median age in years (range)  52 (43–77)
Gender 
 Male  18
 Female  2
Ethnicity 
 Caucasian  14
 Black  5
 Other  1
Karnofsky performance status 
 70  5
 80  7
 90  6
 100  2
Prior therapy 
Chemotherapy 18
 1  Cycle  5
 2  Cycles  10
 3  Cycles  3
Radiotherapy 20
EpCAM expression 
 Positive  18
 Negative  2
Abbreviation: EpCAM, epithelial cell adhesion molecule.Drug Design, Development and Therapy 2008:2 109
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Although tumor bleeding was reported in some patients, 
none of these events were related to VB4-845. Two of the 
events occurred in nontarget tumors and the other two were 
in locations spatially separated from the injection site. Tumor 
bleeding in patients with advanced SCCHN is not unexpected 
(Sittel et al 2001). Four patients died during the course of the 
study, and one patient died after withdrawal from the study 
(withdrawal was due to DLT); however, none of the deaths 
were deemed treatment-related.
Pharmacokinetics
The pharmacokinetic parameters of VB4-845 in the patients’ 
blood were analyzed to evaluate the release of the drug into 
circulation following IT injection. Patients with both lower 
and higher dose levels had detectable VB4-845 in the blood 
(Table 3). The mean Cmax ranged from 10 to 14,997 pg/mL, 
and the mean area under the curve (AUC0–last) ranged from 
64 to 38,802 pg/mL⋅h. Although there was a trend towards 
increased VB4-845 levels at higher dose levels with the 
exception of the 500 μg dose, a high degree of variability 
was evident across each dose. In several patients VB4-845 
was below the limits of detection (7 pg/mL) at one or more 
time points; the high variability and nonlinear kinetics may 
be due to several factors such as vascularization, tumor size 
and antibody neutralization (see below). The mean t1/2 across 
all doses was 4.68 ± 2.54 hours suggesting a rapid clearance 
from the bloodstream. There was no evidence of accumula-
tion of VB4-845 between doses in any of the patients (data 
not shown).
Immunogenicity
The immunogenicity of VB4-845 was examined by analyzing 
the titers of anti-scFv and anti-ETA252–608 antibodies in blood 
samples of patients taken at various time points during the trial 
Table 2 Patients reporting drug-related adverse events
Adverse eventa Drug  dose  (μg/week)        
  100 200  330 500  700 930
 N  = 3b N  = 3b,c N  = 3b N  = 3d N  = 3b N  = 5b,e
Injection site rednessf 1(1)  1      3  (2)  3
Injection site edemaf  1 (1)      1  3 (1)  1
Injection site painf 2    1  1  (1)  1  1
Injection site ulcerf       1   
Fever 1  1  1  1    1
Elevated liver enzymes: AST, ALT          1 (1)  3 (2)g
GGT          1 (1)  1 (1)
Albumin         1
Alkaline phosphatase          1 (1) 
Creatinine         1
Anorexia         3  1  (1)
Anemia  1        1
Cancer  pain   1  1  (1)   
Performance  decrease         1  (1)
Nausea 1        1 
Vomiting         2 
Oral abscess        1   
Headache       1   
Pains in extremity        1   
Tongue edema        1   
Hematuria 1         
Rigors (chills)        1   
Asthenia  (weakness)         1
Fatigue         1
Notes: Numbers in parentheses represent the number of patients with grade 3 or 4 adverse events. aDrug-related events which are possibly, probably or deﬁ  nitely related to 
the study drug. If a patient experienced an adverse event more than once, the event with the highest grade was tabulated. bOne patient discontinued due to death, deemed to 
not be treatment related. cTreatment was discontinued at one patient’s request. dTreatment was discontinued in one patient due to adverse event. eTreatment was discontinued 
in two patients due to adverse events. f Local injection toxicity scale based on the injection site reaction event in NCI CTC version 2.0: pain, erythema and swelling of the skin 
or mucosa limited to the injection site and an area 3 cm adjacent to the tumor borders was classiﬁ  ed as grade 1; a similar reaction in an area 3 cm and  6 cm adjacent to 
the tumor borders classiﬁ  ed as grade 2. Extension of the area to 6 cm, or the presence of necrosis or ulceration that was severe or prolonged and required surgery, or arterial 
bleeding projecting from the wound which was self-limited with pressure deﬁ  ned grade 3 toxicity. Grade 4 injection toxicity was a life-threatening or chronically disabling local 
reaction or a hemorrhage. gDLT.
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; DLT, dose-limiting toxicity; GGT, gamma-glutamyltranspeptidase; NCI CTC, National Cancer 
Institute common toxicity criteria.Drug Design, Development and Therapy 2008:2 110
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(Table 4). Prior to treatment, 15 of 19 patients had antibodies 
to the exotoxin portion of the recombinant fusion protein. Over 
the course of VB4-845 treatment, an increasing number of 
patients developed anti-ETA252–608 responses, and by the end, 
of the study, all patients analyzed had detectable anti-ETA252–608 
titers. Antibody titers beyond the limit of detection to the scFv 
portion of VB4-845 (anti-scFv) were not evident until day 15 
but developed over the course of the study with 15 of 17 ana-
lyzable patients having detectable anti-scFv titers by the end 
of treatment (Day 28); the mean anti-scFv titers were consid-
erably lower than the mean anti-ETA252–608 titers (19,500 vs. 
124,100). For some patients the anti-ETA and anti-scFv titers 
remained elevated up to a month after dosing (Day 56).
Detectable antibody reactivity was observed against 
both the ETA and scFv moieties prior to initiating treatment 
(Day 1). Only the antibody reactivity against the ETA portion 
was considered noteworthy as the antibody titer was shown 
to be higher on Day 8 relative to Day 1 whereas the scFv titer 
was unchanged. Of the 15 patients that were presensitized 
to the ETA exotoxin, the plasma from seven elicited an 
inhibitory effect in a VB4-845-mediated cytotoxicity assay 
indicating the presence of neutralizing antibodies (data not 
shown). For six of the seven patients, the effect of neutraliz-
ing antibodies was concurrent with below detectable levels of 
VB4-845 in patient plasma in the pharmacokinetic analysis. 
Even though all analyzable patients had eventually developed 
an immune response to VB4-845, the effect of neutralizing 
antibodies was only demonstrated in seven patients.
Although evaluation of efficacy was not a primary 
objective in this study, we obtained preliminary data that 
indicated a notable reduction (ten patients) or stabilization 
(four patients) of tumor growth in 16 EpCAM-positive 
patients based on radiographic and caliper measurements. 
Of the EpCAM positive patients that demonstrated a tumor 
response, four patients had complete clinical resolution of 
their tumors. An example of a complete response in one 
patient is seen in computed tomography scans and digital 
photographs (Fig. 1a–d). In addition, three out of the four 
patients with complete responses had regression or complete 
resolution of noninjected lesions adjacent to the injected 
tumors. One patient with dermal metastasis, which is rare 
and often associated with a poor prognosis in SCCHN, 
experienced resolution of noninjected cutaneous metastases 
(Fig. 1e–f). This patient presented with a lesion in the right 
submandibular region that was the principal injected tumor, 
along with cutaneous lesions; none of these cutaneous lesions 
were injected. The principal tumor achieved a complete 
response, and the cutaneous lesions visibly resolved.
Table 3 Pharmacokinetics of VB4-845 dosing
Dose level (μg) #  of  patients  Cmax (pg/mL)  AUC0–last (pg/mL⋅h) t1/2 a (h)
100 2  1145  ± 1619  1955 ± 2764  3.38 (1)
200 3  2090  ± 1815  6915 ± 6072  3.85 ± 0.49 (2)
330 3  1269  ± 2199  1886 ± 3266  1.84 (1)
500 3  10  ± 17  64 ± 111  NDb
700 3  10,936  ± 9772  38,802 ± 38,955  4.45 ± 1.00 (2)
930 5  14,997  ± 21,903  32,384 ± 38,844  5.95 ± 3.36 (4)
Notes: aValues in parentheses represent the number of patients used for t1/2 determination. bNot determined. Most of the values were lower than the limit of quantiﬁ  cation. 
The inability to detect VB4-845 is most likely due to the presence of pre-existing anti-ETA antibodies found in 2 out of 3 patients in the 500 μg dose level. The lower and 
upper limits of quantiﬁ  cation were 7 pg/ml (0.1 pM) and 112 pg/mL (1.6 pM), respectively with intra- and inter-day variability of <25%. Plasma pharmacokinetic variables were 
calculated based on all time points using WinNonlin Pro (version 4.1, Pharsight Corporation, Mountain View, CA, USA).
Abbreviations: AUC, area under the curve; ETA, Pseudomonas exotoxin A; ND, not determined.
Table 4  Antibody responses to the scFv and exotoxin portions of VB4-845
Day  ETA response    scFv response 
 Patientsa  Mean Titer (x 10−3) Patientsa  Mean Titer (x 10-3)
1  15/19  2.5 (1.2)  6/19  1 (1)
8 7/19  4.2  (1.6)  0/19  ND
15 13/18  77.6  (1.7)  11/18  5.7  (1.3)
22  16/18  125.0 (1.5)  15/18  12.4 (1.4)
28  17/17  124.1 (1.5)  15/17  19.5 (1.3)
56  11/11  181.3 (1.5)  9/11  12.4 (1.4)
Notes: aNumber of patients with detectable response/number of patients evaluated. Mean titer is the calculated geometric mean of those patients with measurable titers 
on that given day. Values in parentheses are the corresponding standard error. Mean titer on day 8 was not determined as all values were below the limit of detection after 
subtracting Day 1 values.
Abbreviations: ETA, Pseudomonas exotoxin A; ND, not determined.Drug Design, Development and Therapy 2008:2 111
Phase I trial of   VB4-845 for SCCHN
a        b  
c         d
e        f  
Figure 1 Resolution of targeted and nontargeted tumors in response to VB4-845 treatment. Digital photograph (a) and corresponding computed tomography scan (b) of the 
targeted tumor lesion in patient A at baseline. Circled regions denote location of the targeted tumor. Digital photograph (c) and corresponding computed tomography scan 
(d) of the VB4-845 treated tumor lesion in patient A at ﬁ  nal visit. Circled regions denote location of the targeted tumor as originally seen at baseline. Digital photograph of 
the location of dermal metastases (arrows) and targeted tumor (circled region) in patient B at baseline (e) and at ﬁ  nal visit (f), respectively.Drug Design, Development and Therapy 2008:2 112
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Discussion
This phase I trial of the safety and tolerability of VB4-845 
IT injections administered once weekly for four consecutive 
weeks indicated that VB4-845 was safe and well-tolerated 
and that adverse events were manageable. The MTD was 
established at 930 μg given once per week as indicated by a 
DLT of elevated liver enzyme levels in two patients at this 
dose level. The most common treatment-related adverse 
events were injection site reactions, fever, gastrointestinal 
disorders, and transiently elevated liver enzymes. Similar 
results were observed in another clinical trial with VB4-845 
administered through IT injections on a daily dosing schedule 
(ﬁ  ve consecutive days) with two cycles of treatment, followed 
by 23 days of rest (manuscript in preparation). The weekly 
mode of administration in the current study was preferred 
over a daily dosing regimen, as it is more convenient for 
patients.
IT administration was chosen to reduce the possibility 
of vascular leak syndrome, a common side effect with some 
immunotoxins (Siegall et al 1997), and to lessen the effect 
of circulating antibodies. In this study, approximately half 
of the patients tested had detectable levels of VB4-845 in 
their blood following IT administration with all patients 
developing antibodies to VB4-845 over the course of the 
trial. This suggests that in some patients, the drug clears from 
the tumor into the systemic circulation. Pseudomonas exo-
toxin is immunogenic, and therefore an antigenic response 
to VB4-845 was anticipated. By the end of the study all 
patients had anti-ETA252–608, and most patients had anti-scFv 
responses. The anti-scFv titers were generally lower than the 
anti-ETA titers and may have resulted from a carrier effect 
because of its proximity to the exotoxin. The presence of 
anti-ETA antibodies in a high proportion of patients prior 
to treatment is possibly due to previous exposure of the 
patient to Pseudomonas (Fitzgerald et al 1989), which may 
result in neutralization and a reduction of drug in circulation. 
Although the antibody response was neutralizing in some 
patients, low or nondetectable levels of VB4-845 could not 
be attributed to neutralizing antibodies in other patients. 
Other potential reasons for the lack of detection of VB4-845 
in the bloodstream of some patients are that only low levels 
of drug move from the tumor into the systemic circulation, 
or that the rapid clearance of the drug from the systemic 
circulation of some patients reduces levels to below the 
limits of detection. High variability from patient to patient in 
pharmacokinetic parameters of intratumorally administered 
biologic immune activators has been previously noted (van 
Herpen et al 2003, 2004).
Preliminary efﬁ  cacy data indicated a notable reduction 
or stabilization of tumor growth in EpCAM-positive patients 
based on radiographic and caliper measurements. This anti-
tumor activity was seen despite the fact that dosing in this 
study was not optimized for therapeutic beneﬁ  t. These results 
complement data obtained in an earlier trial with a daily dos-
ing schedule, where VB4-845 also showed antitumor activity 
(manuscript in preparation). In some instances, antitumor 
effects were observed in adjacent and distal noninjected 
tumors. In particular, one patient with dermal metastasis, a 
condition often associated with late stage disease and poor 
prognosis (Cole et al 1995; Pitman et al 1999; Yoskovitch et al 
2001; Dequanter et al 2005), exhibited complete resolution 
of these secondary tumors.
Currently therapeutic options for the treatment of SCCHN 
are limited, and survival rates after failure of ﬁ  rst line treatment 
options are very low (León et al 2005). A novel alternative 
currently under investigation for the treatment of SCCHN is 
the application of photodynamic therapy (PDT). PDT provides 
a noninvasive treatment approach to tumor cell killing through 
the activation of photosensitizing drugs and the release of 
singlet molecular oxygen (Jerjes et al 2007). Clinical results 
achieved with PDT in the treatment of SCCHN to-date have 
been comparable with or better than standard treatment pro-
tocols but without the associated morbidity. However, as the 
photosensitizer is generally administered systemically, the 
drug is free to accumulate throughout the body and as such 
can lack the speciﬁ  c targeting of other methods.
Monoclonal antibody based therapies provide a targeted 
approach that can be applied in combination with traditional 
therapies. For example, a phase III study combining Cetux-
imab and radiotherapy signiﬁ  cantly prolonged progression-
free survival in patients with locally advanced inoperable 
SCCHN (Bonner et al 2006), and Cetuximab has also shown 
antitumor activity in two phase II trials in combination 
with chemotherapy (Baselga et al 2005; Herbst et al 2005). 
However, combination therapy has yet to establish efﬁ  cacy 
above the current standard of chemoradiotherapy (Posner 
and Wirth 2006).
This study has established an MTD for weekly dosing of 
VB4-845, as well as demonstrating that repeated IT delivery 
of VB4-845 was not limited by immunogenicity and was 
well tolerated. Preliminary efﬁ  cacy results also indicated a 
positive outcome to VB4-845 therapy in EpCAM-positive 
patients. These promising results will be extended in a larger 
placebo-controlled clinical trial with optimized dosing to 
demonstrate the effectiveness of VB4-845 as a therapeutic 
agent for the treatment of SCCHN.Drug Design, Development and Therapy 2008:2 113
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